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Abstract
Serum proteins are routinely used to diagnose diseases, but are hard to find due to low sensitivity in screening the serum
proteome. Public repositories of microarray data, such as the Gene Expression Omnibus (GEO), contain RNA expression
profiles for more than 16,000 biological conditions, covering more than 30% of United States mortality. We hypothesized
that genes coding for serum- and urine-detectable proteins, and showing differential expression of RNA in disease-damaged
tissues would make ideal diagnostic protein biomarkers for those diseases. We showed that predicted protein biomarkers
are significantly enriched for known diagnostic protein biomarkers in 22 diseases, with enrichment significantly higher in
diseases for which at least three datasets are available. We then used this strategy to search for new biomarkers indicating
acute rejection (AR) across different types of transplanted solid organs. We integrated three biopsy-based microarray studies
of AR from pediatric renal, adult renal and adult cardiac transplantation and identified 45 genes upregulated in all three.
From this set, we chose 10 proteins for serum ELISA assays in 39 renal transplant patients, and discovered three that were
significantly higher in AR. Interestingly, all three proteins were also significantly higher during AR in the 63 cardiac
transplant recipients studied. Our best marker, serum PECAM1, identified renal AR with 89% sensitivity and 75% specificity,
and also showed increased expression in AR by immunohistochemistry in renal, hepatic and cardiac transplant biopsies. Our
results demonstrate that integrating gene expression microarray measurements from disease samples and even publicly-
available data sets can be a powerful, fast, and cost-effective strategy for the discovery of new diagnostic serum protein
biomarkers.
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Introduction
The utility of serum and plasma proteomic techniques to find
diagnostic biomarkers has received considerable attention and
investment in recent years. However, the limited sensitivity of mass
spectrometers, the dynamic range of protein concentrations, and
the presence of high abundance proteins in blood samples are
major challenges in the identification and verification of potential
protein biomarkers in peripheral blood [1].
Since the development of gene expression microarrays more than
a decade ago[2,3], many microarraystudies havebeen usedtostudy
changesinmRNAtranscriptsindisease-related tissues.Considerable
microarray data have been deposited into international repositories
including the Gene Expression Omnibus (GEO) [4] and ArrayEx-
press [5], with at least 30% of US mortality already covered [6].
Integration of publicly-available microarray data has been used to
show commonalities across cancers [7], suggest candidate gene
variants associated with disease [8], associate relations with studied
phenotypes [9], and even to validate gene-expression-based
diagnostics for US Food and Drug Administration approval [10].
Although microarrays measure the relative abundance of mRNA
transcripts, their translated proteins are also likely to be differentially
present in diseased tissue and possibly even secreted or detectable in
the blood. Rhodes et al first proposed to predict serum protein
biomarkers by integrating cancer gene expression data from
Oncomine and filtering the list with Gene Ontology annotation of
‘‘extracellular’’, ‘‘extracellular matrix’’, and ‘‘extracellular space’’
[11]. They predicted ten serum protein biomarkers for ovarian
cancer and found that PRSS8 had previously been known to be an
accurate biomarker for ovarian carcinoma.
PLoS Computational Biology | www.ploscompbiol.org 1 September 2010 | Volume 6 | Issue 9 | e1000940We have previously developed a methodology to determine
gene expression signatures across 238 diseases from GEO. We
have found that the molecular signature of disease-specific RNA
across tissues is more prominent than the signature of tissue-
specific expression patterns [12]. We hypothesized that RNA
measurements in diseased tissue could be used to identify
candidate serum protein biomarkers of disease. We also hypoth-
esized that integrating data sets from similar conditions could be
used to find protein biomarkers applicable across the related
conditions. Finally, we tested whether focusing only on those genes
that code for proteins known to be detectable in serum and urine
(here termed biofluids), using previously published resources might
improve our specificity [13]. We then evaluated the general and
specific performance of this Integrated RNA Data Driven
Proteomics (IRDDP) method to suggest protein candidates across
hundreds of diseases.
One field in urgent need of non- or minimally invasive protein
biomarkers is solid-organ transplantation [14]. The diagnosis of
acute allograft rejection (AR) is currently based on functional and
histological grounds. The latter approach requires an invasive
procedure in order to obtain sufficient representative tissue for
pathology [15,16], though blood-based RNA diagnostics are
successfully being validated [17]. Additional serum biomarkers are
still needed to reduce or avoid invasive diagnostic procedures for
AR [16,18,19]. Many efforts have been made to identify such
biomarkers [20]. For example, in renal transplant rejection,
significantly increased protein concentrations of VEGF have been
observed in serum and urine [21,22,23]. Increases in the following
other entities have also been observed: CXCL9 in urine [24],
soluble CD44 in plasma [25], ADL in serum [26], and TNF-alpha
in serum [27]. HLA class I (ABC) protein levels were recently found
to be elevated on the surfaces of peripheral blood CD3+/CD8+ T
lymphocytes in AR at 14 and 21 days after renal transplantation
[28]. However, there is still no reliable blood-based protein test to
diagnose AR and none of these biomarkers has been shown to be
universally present across all transplanted organs[14].
At the same time, a previous study also showed that there are
similarities in the biology of the processes involved in the rejection
of different transplanted solid organs [29]. Informed by these
previous successes and efforts, we applied the IRDDP method here
to search for blood-detectable proteins for acute rejection across
different transplanted organs.
Results
Our first goal was to test the hypothesis that blood- and urine-
detectable protein biomarker candidates could be identified by
using tissue-based gene expression microarray data. Using
previously described methods [12], we acquired gene expression
data sets representing 41 diseases, as well as control tissue samples
for each from GEO [4], the largest international repository for
gene expression microarray data with over 400,000 samples at the
time of this writing.
We applied our IRDDP methodology to each disease. First, we
calculated a set of differentially expressed genes for each disease
using the RankProd meta-analysis package at a percentage of false
prediction (pfp) #5% [30]. For diseases with multiple microarray
data sets, we included genes that were differentially expressed in at
least one of the data sets. We then filtered the gene sets through a
list of 3,638 proteins with known detectable abundance in serum,
plasma, or urine. The list was created from public sources
[31,32,33,34] and has been described [13]. This effort yielded a set
of candidate protein biomarkers for each disease (Dataset S1).
For each disease, we then compared our candidate biomarkers
with known diagnostic protein biomarkers in the GVK BIO
Online Biomarker Database (GOBIOM). GIOBIOM is an
independent manually curated knowledge base taken from global
clinical trials, annual meetings, and journal articles [35]. As of this
writing, GOBIOM contains 6,098 known biomarkers for 368
therapeutic indications with 23,166 unique references. For 22/41
diseases, known diagnostic protein biomarkers were enriched in
our predicted protein sets (p,0.05, Fisher’s exact, Table 1). In 9/
11 diseases for which at least three data sets were available, known
diagnostic protein biomarkers were even more significantly
enriched in our predicted protein sets. The -log(p-value) in
diseases with three or more data sets (n=11) was significantly
higher than those in diseases with fewer than three data sets
(n=30; p=0.004, Fisher’s exact, Fig. 1). Of the remaining 19
diseases, 11 were represented by only a single gene expression data
set. Therefore, we concluded that the more gene expression
datasets for a disease, the more likely known biofluid protein
biomarkers are going to be significantly differentially expressed
across any one of those data sets, suggesting the likelihood of
finding new biomarkers increases with more available data sets.
While this finding is not at all surprising, we were able to conclude
that joining as few as three experiments could statistically
significantly improve the performance to rediscover clinically
validated protein biomarkers across 41 diseases.
We then applied IRDDP to the specific problem of finding
serum biomarkers for the diagnosis of transplant acute rejection
(AR). We integrated three biopsy-based gene expression micro-
array studies from pediatric renal, adult renal [36], and adult
cardiac [29] transplantation, identified genes commonly upregu-
lated in AR compared to stable graft function, and then measured
the abundance of proteins encoded by these genes in serum to
identify cross-organ AR protein biomarkers (Fig. 2). The first of
the three studies was performed in pediatric renal transplantation.
It compared gene expression profiles in biopsy samples from 18
AR patients and 18 patients with stable graft function (STA) at the
absence of AR and any other substantive pathology (Table S1).
Using Significance Analysis of Microarrays [37], we found 2,805
genes with increased expression in AR biopsies (q-value #0.05;
fold change $2).
Author Summary
Protein biomarkers in the blood are urgently needed for the
diagnosis of a wide variety of diseases to improve health
care. We aim to find a fast and cost-effective strategy to
discover diagnostic protein biomarkers. Hundreds of
diseases have already been investigated using microarray
technology, measuring the mRNA expression of all genes in
the disease-damaged tissues. We analyzed biopsy-based
microarray data for 41 diseases in the public repository,
identified genes with dysregulated mRNA expressions and
detectable-protein abundance in the blood, and predicted
them as candidate diagnostic protein biomarkers. We found
that clinically and preclinically validated diagnostic protein
biomarkers were significantly enriched in our predicted
protein candidates for 22 diseases. We then measured the
concentrations of ten predicted protein biomarkers in the
serum samples from 39 renal transplant patients. Three of
them were confirmed to be diagnostic of acute rejection
after renal transplantation. All three proteins were further
confirmed to be diagnostic of acute rejection in 63 cardiac
transplant recipients. Our results show that publically
available genome-wide gene expression data on disease-
damaged tissues can be effectively translated into diagnos-
tic protein biomarkers.
Microarray Data Yields Serum Protein Biomarkers
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41 diseases.
Disease GEO Accession Number
Predicted Protein
Biomarkers*
Known Protein
Biomarkers** Overlap P value
$
Breast Cancer GSE53, GSE1378, GSE1379, GSE1872,
GSE2155, GSE2429, GSE2528, GSE3744,
GSE4382
1845 134 63 2.26610
224
Lung Cancer, Non-Small Cell GSE1037 1064 44 23 2.21610
211
Diabetes Mellitus, Type 2 GSE710, GSE642, GSE2470, GSE3068,
GSE6428
439 17 9 5.30610
29
Chronic Obstructive Pulmonary Disease GSE475, GSE1650, GSE3320, GSE10964 217 18 5 5.14610
26
Melanoma GSE3189, GSE4587 1005 49 13 3.91610
25
Alzheimer’s Disease GSE1297, GSE5281 (3 data sets) 1414 19 8 8.04610
25
Crohn’s Disease GSE1710, GSE3365, GSE6731 1515 9 6 1.94610
24
Cystic Fibrosis GSE765, GSE769, GSE3100 234 8 3 4.56610
24
Hypercholesterolemia GSE3889 712 3 3 4.81610
24
Wilm’s tumor GSE2712 192 2 2 6.53610
24
Sickle Cell Anemia GSE9877 1437 7 5 1.15610
23
Myelodysplastic Syndromes GSE2779, GSE4619 779 10 4 1.88610
23
Leukemia, Chronic Lymphocytic GSE2466 671 21 7 2.90610
23
Lung Cancer, Small Cell GSE1037 986 4 3 4.44610
23
HIV Infection GSE2171, GSE2504, GSE6740 367 24 4 7.34610
23
Prostate Cancer GSE1413, GSE3868 302 88 6 0.012
Diabetes Mellitus, Type 1 GSE710, GSE1623, GSE1659, GSE2254,
GSE4616
214 9 2 0.018
Lymphoma GSE60, GSE3211 28 27 2 0.023
Transitional Cell Carcinoma GSE3167 899 3 2 0.025
Liver Cirrhosis GSE1843, GSE6764 905 4 2 0.028
Ulcerative Colitis GSE1710, GSE3365, GSE6731 1301 7 3 0.030
Heart Failure GSE1988 96 2 1 0.044
Colon Cancer GSE2178, GSE4107 451 17 2 0.096
Rheumatoid Arthritis GSE1919, GSE2053, GSE3592 307 15 2 0.098
Cardiomyopathy GSE1869, GSE5406 1172 5 2 0.11
Thyroid Cancer GSE5364 933 6 2 0.12
Obesity GSE474, GSE4692, GSE4697 161 10 1 0.13
Atherosclerosis GSE363 25 21 1 0.15
Sarcoidosis GSE1907 369 7 1 0.51
Hypertension GSE1674 10 11 0 1
Vitamin B12 Deficiency GSE2779 3 2 0 1
Testicular Cancer GSE1818 100 14 0 1
Bipolar Disorder GSE5389 267 1 0 1
Schizophrenia GSE4036 116 5 0 1
Leukemia, Acute Myeloid GSE2191 148 11 0 1
Parkinson’s Disease GSE7621 100 6 0 1
Thymic Carcinoma GSE2501 65 6 0 1
Obstructive Sleep Apnea GSE1873 34 3 0 1
Osteoarthritis GSE1919 60 3 0 1
Inflammatory Bowel Disease GSE4183 619 2 0 1
Multiple Sclerosis GSE10064 11 3 0 1
*Number of genes that were differentially expressed in any one of the disease tissues at the mRNA level (fpf#0.05, RankProd R package) with detectable protein
abundance in the biofluid proteome database (see Methods).
*Number of known diagnostic protein biomarkers in clinical and preclinical studies from the GVK BIO Online Biomarker Database (GOBIOM).
**Number of correctly predicted diagnostic protein biomarkers.
$P values were calculated to evaluate whether known protein biomarkers were significantly enriched in our predicted genes using Fisher’s exact test.
doi:10.1371/journal.pcbi.1000940.t001
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transplant studies that we retrieved from GEO. One study
compared biopsy samples from 13 AR patients with 19 STA
samples after adult kidney transplant (GEO dataset GDS724 [36]).
The study yielded 2,316 upregulated AR genes with q-values
#0.05. The second study compared 12 AR biopsy samples with 13
non-rejection samples after cardiac transplant (GEO series
GSE4470 [29]). It yielded 283 upregulated AR genes with q-
values #0.05. By intersecting the three data sets, we identified a
gene expression signature containing 45 genes in common,
irrespective of the specific studies or transplanted organs (Table
S2). These genes are hereafter referred to as the ‘‘common-AR’’
set of genes.
To evaluate the significance of finding 45 genes in common, we
shuffled the gene labels across the three data sets and repeated the
entire analysis 100,000 times. In random performance, the
number of intersecting genes was normally distributed around
n=9 (Fig. S1), suggesting a false discovery rate of 20%. This result
also suggested that the probability of finding 17 or more
commonly dysregulated AR genes by chance was less than 1%,
and that the probability of finding 24 or more of them by chance
was less than 1610
25.
We next retrieved mRNA expression data for each common-
AR gene across 74 tissue and cell types from SymAtlas [38], and
identified the cell type with the highest expression. Surprisingly,
our common-AR genes were most enriched in CD14+ monocytes
(p=0.003, Fisher’s exact). Seven of the 45 common-AR genes had
their highest expression levels in CD14+ monocytes: they were
CD44, IL10RA, S100A4, IGSF6, CTSS, CASP4, and SCAND2. Our
results suggest an important role for activated pro-inflammatory
monocytes in transplant rejection. This finding is consistent with
recent reports that monocyte/macrophage activation might
induce inflammation, leading to impairment of graft function in
renal transplant patients [39].
Wethenanalyzedthefunctionsofthe45common-ARgenesusing
Ingenuity Pathway Analysis. As expected, 28 of the 45 common-AR
genes were involved in the inflammatory response (p=3.37610
217,
Fisher’s exact; p,3.56610
23 after Benjamini-Hochberg multi-test
correction). Furthermore, 23 common-AR genes were involved in
cell-mediated immune responses, (p=3.34610
215;p ,2.97610
23,
Benjamini-Hochberg correction). Finally, 23 common-AR genes
were involved in a single pathway associated with inflammatory
responses, antimicrobial responses, and cellular movement regulated
by STAT-1 (Fig. S2).
ELISA kits were available for ten of the 45 candidate proteins,
including six proteins known to be in biofluids and four outside. We
measured all ten proteins in a pilot study of serum samples collected
within 24 hours after biopsy from an independent set of 19 patients
with biopsy-proven AR and 20 patients with absence of AR or any
other substantive pathology (STA). The patients were from a
pediatric and young adult renal transplant study. No patients were
positive for BK virus infection, and no patient samples in the ELISA
study were matched with samples used in the microarray study. The
AR/STA samples were matched for recipient and donor gender,
age, type of immunosuppression, time post-transplant, race, and
type of end stage renal disease (Table S3).
Figure 1. Identifying protein biomarkers was more likely if $3 gene expression data were available. We calculated Fisher’s exact test
association p-values between predicted and known protein biomarkers for each of 41 diseases (Table 1). The values are plotted on the y-axis. Known
protein biomarkers were more likely to be rediscovered (Mann-Whitney U p-value=0.004) for the 11 diseases represented by $3 gene expression
data sets (left notched box plot, median p-value=5610
24), versus those 30 diseases represented by ,3 data sets (right, mean p-value=0.12). A
notch was added around the median p-value in each box to indicate the significance of difference. When the notches about two medians do not
overlap, the medians are roughly significantly different at about a 95% confidence level [54] . The circles are outliers.
doi:10.1371/journal.pcbi.1000940.g001
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lated in the AR serum samples compared to the STA samples after
renal transplantation (Fig. 3). They were PECAM1 (also known as
CD31 antigen, or platelet/endothelial cell adhesion molecule),
CXCL9 (MIG, chemokine ligand 9), and CD44 (hyaluronic acid
receptor). Mann-Whiney U test for significant differences yielded p-
values of 1610
23,1 610
24,a n d5 610
23, respectively. Receiver
Operating Characteristics (ROC) curves showed the ability of each
individual protein to distinguish AR from STA (Fig. 3d). The areas
under the ROC curves (AUC) were 0.811, 0.864, and 0.761 for
PECAM1, CXCL9, and CD44, respectively. At optimal perfor-
mance, PECAM1 distinguished AR from STA with 89% sensitivity
and 75% specificity; CXCL9: 78% sensitivity and 80% specificity;
CD44: 80% sensitivity and 75% specificity.
We then measured the concentration of these proteins in a
second pilot study on plasma samples of cardiac allograft recipients
to identify cross-organ AR biomarkers. We compared samples
from 32 AR patients and 31 STA patients. The samples were
matched for demographic characteristics (Table S4). None of them
was infected with CMV. Interestingly, all three markers were
upregulated in AR compared to STA. Mann-Whitney U test for
significant differences yielded p values of 3610
23 (PECAM1),
0.019 (CXCL9), and 4610
23 (CD44) (Fig. 4). The areas under the
ROC curves for distinguishing AR from STA were 0.716, 0.672,
and 0.711 for PECAM1, CXCL9, and CD44, respectively.
We evaluated the performance of a combined panel of
PECAM1 and CXCL9 using a three-fold cross-validation. We
randomly selected two thirds of the samples, trained a multinomial
logistic regression model, and calculated the predictive perfor-
mance on the remaining one third of samples. After repeating the
process 1000 times, the average ROC curves showed an
improvement on cardiac AR diagnosis and no additional
improvement on renal AR diagnosis (Fig. S3), suggesting a large
clinical trial combining PECAM1 and CXCL9 with other
previously found protein biomarkers would be needed to evaluate
the predictive diagnosis of AR. Adding CD44 did not improve the
regression models.
We performed an immunohistochemistry study on our best-
performing marker, PECAM1. The goal of the study was to
compare its protein expression in AR and STA samples from
Figure 2. Identification of cross-organ AR protein biomarkers through integration of gene expression data. We integrated three
microarray studies examining gene expression after rejection in the biopsy samples from pediatric renal, adult renal, and adult heart transplants (the
latter two were retrieved from GEO). We identified 45 genes that were upregulated in common in acute rejection compared to stable graft function.
Among ten proteins we tested by ELISA, the concentrations of three were higher in serum samples from AR patients. The concentrations of the same
three proteins were also higher in AR samples from cardiac transplantation. Immunohistochemistry showed that PECAM1 was increased in AR vs.
stable biopsies in renal, hepatic and cardiac transplantation. All three biomarkers were from our identified AR pathway, and two of them showed
detectable protein abundance in the biofluid proteome database we constructed before. CXCL9 was not listed in our biofluid proteome database,
but is known to have detectable protein abundance [24].
doi:10.1371/journal.pcbi.1000940.g002
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tissue, PECAM1 staining was mainly observed in the endothelial
cells of glomeruli, in peritubular capillaries, and in large blood
vessels. In contrast, examination of staining patterns in AR
biopsies revealed dense infiltrates of PECAM1, as well as positive
lymphocytes and mononuclear cells in the interstitium. Similarly,
dense endothelial PECAM1 staining was observed in the hepatic
and cardiac transplant AR tissues, along with staining in
infiltrating mononuclear cells. We observed only minor endothe-
lial staining in hepatic and cardiac STA tissues. These immuno-
histochemistry results showed significantly increased PECAM1
protein expression in the AR tissues compared to STA tissues
across transplanted organs.
Furthermore, our studies showed that PECAM1 protein was
also significantly upregulated in the serum samples from AR
patients compared with samples from patients with BK virus
infection (n=10, p=0.001, Mann-Whitney U test) and chronic
allograft injury (n=10, p=6610
25, Mann-Whitney U test) after
renal transplantation (Fig. S4). Analysis across hundreds of diseases
using our GeneChaser tool [40] showed that the mRNA
Figure 3. Serum ELISA results of three protein biomarkers in renal transplantation. We measured the protein concentration of ten genes
by ELISA in independent serum samples of 19 AR patients and 20 patients with stable (STA) graft function after renal transplant. The protein
concentrations of PECAM1 (A), CXCL9 (B), and CD44 (C) were higher in the AR serum samples, as shown in the notched boxplots. When the notches
about two medians do not overlap, the medians are roughly significantly different at about a 95% confidence level [54] . The circles are outliers. P-
values were calculated using the Mann-Whitney U test. One of the AR samples was inadvertently lost during the PECAM1 experiment and could not
be recovered. (D) Areas under the Receiver Operating Characteristic (ROC) curves used to distinguish AR from STA were 0.811, 0.864, and 0.761 for
PECAM1, CXCL9, and CD44, respectively.
doi:10.1371/journal.pcbi.1000940.g003
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cancers, but not in other potential confounding conditions, such as
infection and hypertension (http://tinyurl.com/yhq9h3k). These
results suggest that PECAM1 is a serum marker specific for
allograft acute rejection, irrespective of the transplanted organ.
Finally, as mentioned above, 23 of our 45 common-AR genes
were involved in a single pro-inflammatory pathway regulated by
STAT-1 (Fig. S2). Among the ten proteins we tested by ELISA,
five were within this pathway and five were outside of it. All five
proteins outside the pathway failed validation, while three of the
five proteins inside it were validated as AR markers. The 60%
success rate from within this single pathway suggests that it is likely
to represent a common functional pathway in AR across
transplanted organs. Other novel AR protein markers are likely
to be found from the remaining 18 common-AR genes/proteins
inside this pathway that have not yet been tested by ELISA (Fig.
S2). These proteins include CD2, Cathepsin S, and SH2D2A.
Discussion
We developed an Integrated RNA Data Driven Proteomics
(IRDDP) method, which exploits the link between RNA changes
in disease-affected tissue with serum detectable proteins coded by
those RNA, yielding candidate proteins diagnostic for those
Figure 4. Plasma ELISA of three protein biomarkers in cardiac transplantation. We measured the protein concentrations of PECAM1 (A),
CXCL9 (B) and CD44 (C) by ELISA in the plasma of 32 AR patients and 31 STA patients after cardiac transplantation. All three proteins have statistically
significantly higher concentration in the AR serum samples, compared to STA as shown in the notched box plots. P-values were calculated using the
Mann-Whitney U test. (D) In ROC curves used to distinguish AR from STA, the areas under the curves were 0.716, 0.672, and 0.711 for PECAM1, CXCL,
and CD44, respectively.
doi:10.1371/journal.pcbi.1000940.g004
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to suggest candidate protein biomarkers for 22 diseases, and have
shown the enrichment of known clinically and pre-clinically
validated protein biomarkers in these candidate biomarkers. We
applied our method to new and publicly-available microarray
measurements on solid-organ transplantation, and identified and
validated three cross-organ serum protein biomarkers for trans-
plant rejection. Our results demonstrate that the integration of
gene expression microarray measurements from disease samples,
and even publicly-available data sets, can be a powerful, fast, and
cost-effective strategy for discovering diagnostic serum protein
biomarkers.
We found that PECAM1, CXCL9 and CD44 proteins were
significantly upregulated in the serum/plasma samples of both
renal and heart transplant patients with acute rejection compared
with patients with stable graft function. The abundance of CXCL9
Figure 5. In situ PECAM1 staining in acute rejection and stable patients in renal, hepatic, and cardiac allograft biopsies. (A) Acute
rejection in a renal allograft biopsy with PECAM1 positive infiltrating lymphocytes and monocytes; endothelial cell staining occurred in glomeruli and
peritubular capillaries. (B) In a stable graft renal allograft biopsy, PECAM1 staining occurred only in endothelial cells in glomeruli and peritubular
capillaries. (C, E) Dense staining was observed in AR tissues after hepatic (C) and cardiac (E) transplants in infiltrating mononuclear cells and
endothelial cells of capillaries and larger blood vessels. In hepatic (D) and cardiac (F) transplant biopsies from stable grafts, weak endothelial cell
staining was observed (magnification 6400).
doi:10.1371/journal.pcbi.1000940.g005
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previously been shown to increase in renal AR compared with
STA. In addition, macrophage surface PECAM1 can distinguish
lung transplant rejection [41] but is not diagnostic in mouse
models of cardiac transplant rejection [42]. But to our knowledge,
this study is the first to show all three markers as cross-organ AR
protein biomarkers in human serum or plasma. Our best marker,
serum PECAM1, identified renal AR with 89% sensitivity, 75%
specificity, 26% PPV, and 99% NPV at 9% prevalence[43],
suggesting its potential clinical usage to monitor transplant patients
to decrease the number of biopsies. We have focused on the
biomarkers that were upregulated in AR because that was what
most clinic tests are using. Proteins downregulated in AR could
potentially be used for diagnosis as well, and we have predicted
both up and downregulated proteins for 44 diseases in Table 1 and
Dataset S1.
We found that the likelihood of finding protein biomarkers
indicative for a disease increases with the number of available gene
expression datasets. Many meta-analysis methods have been
shown to improve the identification of differentially expressed
genes [44]. The identification of protein biomarkers might be
improved through more sophisticated meta-analysis methods, such
as the Rank Product method [30], measurements of concordance
among data sets [45], and the identification of common features
for diagnostic protein biomarkers. Filtering differentially expressed
genes through known proteins detectable in biofluids may also
improve specificity.
Future work will involve taking markers validated in our pilot
studies of cross-organ AR and testing their clinical utility in
blinded prospective studies. These studies might also elucidate the
prognostic value of these markers. Given that hundreds of
thousands of microarray measurements are now publicly available
and that this number is growing, RNA data-driven proteomics
could provide hundreds of serum and urine biomarkers for other
diseases.
Methods
Ethics Statement
This study was approved by the Stanford University Institu-
tional Review Board. Written informed consent was obtained from
all the subjects.
Identification of differentially expressed genes
As previously described [12], we identified microarray exper-
iments containing both disease and normal control tissues for 280
diseases from the NCBI Gene Expression Omnibus (GEO) [4],
calculated differentially expressed probes with percentage of false
prediction (pfp) #5% using the RankProd R package [30], and
converted probe IDs to Entrez Gene IDs using AILUN [46]. For
genes with multiple probes, the probes with the most significant
pfp values were used. For diseases with multiple data sets, we used
genes that were differentially expressed in at least one data set.
Prediction of protein biomarkers
We have previously constructed a human biofluid proteome
database [13] with known serum- and urine- detectable proteins
containing data from the HUPO Plasma Proteome Project [31], a
non-redundant list from the Plasma Proteome Institute [32], the
MAPU Proteome database [47], and the Urinary Exosome
database [48]. We filtered the differentially expressed gene sets
with our human biofluid proteome database to yield potential
protein biomarkers for each disease.
Enrichment of known protein biomarkers
We downloaded all diagnostic protein biomarkers from the
GVK BIO Online Biomarker Database (GOBIOM) [35] with a
selection of Biochemical in Nature and Diagnosis in Application,
and limited the retrieval to those with valid Entrez Gene IDs
annotated as Protein in Chemical Nature. We mapped clinical
indications in this database to disease concepts represented in the
Unified Medical Language System (UMLS) [49], and matched
them to the disease concepts curated in our microarray data. We
used the microarray data to identify 41 diseases with predicted
biomarkers and are known protein biomarkers in GOBIOM. For
each disease, we calculated the enrichment p-values between the
predicted and known protein biomarkers using Fisher’s exact test
in R.
Patients and samples
We collected 18 acute rejection (AR) and 18 stable (STA) biopsy
samples from pediatric renal allograft recipients at the Stanford
Hospitals, and measured gene expression profiles by microarrays.
AR and STA samples were matched for recipient and donor
gender, age, donor source, race, time post-transplant, HLA
matches. Furthermore, all patients were under the same double
(Tacrolimus and MMF) or triple immunosuppression protocols
(Tacrolimus, MMF and steroid), and all had received Daclizumab
induction therapy [50]. Mean and standard deviation data for
patient demographic and clinical variables are provided in Table
S1. The difference in the sample collection time between AR and
STA was caused by two AR samples collected at 69 and 97
months after transplant. The remaining 16 AR samples were
collected at 967 months after transplant, the same as that of stable
patients. Removing the two late-stage AR samples only caused
minor changes in the AR signature. A sample was categorized as
AR with biopsy proven according to the Banff classification [51]
on tubulitis, interstitial inflammation, glomerulitis, and vasculitis
(n=18, Banff grade samples were IA, IB, and IIA not including
border line). Samples were categorized as STA (n=18) if AR and
any other substantive pathologies were absent. We also required
stable graft function on protocol biopsy, which we conducted at 3,
6, 12, and 24 months after transplantation and for graft
dysfunction [50,52]. None of patients was infected with BK virus.
All pathology analyses were performed by a single blinded
pathologist (NK) at Stanford University.
For ELISA experiments on renal transplant serum samples, we
used previously collected serum samples from 19 AR and 20 STA
patients who were not infected with BK virus. All serum samples
were obtained within 24 hours of a clinically indicated or protocol
graft biopsy, and each sample was matched with the patient’s
biopsy. AR samples were biopsy-proven according to the Banff
classification (IA, IB, IIA, IIB, not including border line). For
specificity testing, an additional 10 samples were collected from
patients with chronic allograft injury, who were defined as having
an IFTA score $1 [51]. Ten samples were collected from renal
transplant patients with BK virus infection. We also collected
plasma samples from 32 AR patients and 31 STA patients without
CMV infection after cardiac transplant at Stanford Hospitals. To
minimize loss in sample processing, plasma was directly used in the
ELISA study. Acquisition of samples in both studies was approved
by the Stanford University Institutional Review Board. All AR
samples were graded as ISHLT grade 3A or 3B. Stable samples
showed an absence of AR and any other substantive pathology.
Microarray experiments
Total RNA used for first-strand cDNA synthesis using a T7
promoter-linked oligo(dT) primer following the standard protocol
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Part. 900493). After second strand cDNA synthesis, biotin-labeled
cRNA was prepared in an in vitro transcription reaction using a
GeneChip IVT Labeling Kit (Affymetrix). Ten micrograms of
fragmented cRNA was used for hybridization on Affymetrix
Human Genome U133 Plus 2.0 microarrays according to the
manufacturer’s instructions. The raw and processed data have
been deposited into GEO (accession ID; GSE14328).
Microarray data analysis
All three datasets (pediatric renal, adult renal, and adult heart)
were normalized by the quantile-quantile method using dChip
software[53]. Probes significantly upregulated in AR versus STA
were identified using Significant Analysis of Microarray (SAM; q
#0.05) [37]. All probes associated with AR were linked to Entrez
Gene IDs using AILUN [46]. We limited AR genes as significantly
upregulated in AR compared to STA. We found 9,086 genes
associated with pediatric renal AR, 2316 in adult renal AR, and
283 in heart AR.
The numberof heart AR genes wassignificantly less than those of
kidney AR genes due to different platforms and organs. Publicly
available heart AR data came from studies that used a 70mer
spotted array from NIH/NIAID (GEO accession numbers
GPL1053 and GSE4470). The array contained 8972 probes that
corresponded to 8437 Entrez Gene Ids. This array was smaller than
theAffymetrixU133 plus2.0arrayused forthe pediatricrenalstudy
and the Affymetrix U95 array used for the publicly available adult
renal study (GEO accession numbers GPL91 & GDS724).
To make the number of AR genes comparable between
pediatric and adult renal studies, we added an extra filter. We
included only genes with a fold change $2 in the pediatric renal
study. We obtained 2,805 pediatric renal AR genes, 2,316 adult
renal AR genes, and 283 heart AR genes (Fig. 2). When we
intersected these three AR gene lists, we found 45 common
upregulated AR genes irrespective of transplanted organs.
ELISA validation
Ten proteins in serum were measured by using commercial
ELISA kits. ELISA kits for PECAM1 (Cat. No. ab45910), CD44
(Cat. No. ab45912), and SELL (Cat. No. ab45917) were pur-
chased from ABCam Inc (Cambridge, MA); an ELISA kit for
SA100A4 (Cat. No. CY-8059) was purchased from MBL Inter-
national (Woburn, MA); ELISA kits for CCL4 (Cat. No. DMB00),
CXCL11 (cat. No. DCX110) and CXCL9 (cat. No. DCX900)
were purchased from R&D Systems (Minneapolis, MN). An
ELISA kit for STAT-1 (cat. CBA034) was purchased from
Calbiochem (Gibbstown, NJ); an ELISA Kit for BIRC5/Survivin
(Cat. No. 900-111) was purchased from Assay Designs (Ann
Arbor, MI), and an ELISA assay for CCL8 was developed using
the DuoSet ELISA Development System for human CCL8/MCP-
2 from R&D Systems (Cat. No. DY281).
Sample, reagent, and buffer preparation were done according to
manufacturer manuals, and the assay was performed by following
manual instructions exactly. Microwell plates were read by a
SPECTRAMax 190 microplate reader (Molecular Devices,
Sunnyvale, CA). Protein concentrations were determined from a
standard curve generated from standards supplied with the kits.
Protein concentrations of PECAM1, CXCL9 and CD44 in the
plasma samples of heart transplant patients were also measured
with the ELISA kits specified above.
Immunohistochemistry
Immunohistochemical staining was performed on 4 mm sections
obtained from formalin-fixed paraffin embedded tissues using
mouse monoclonal anti-human antibodies directed against
PECAM-1 (DAKO, Carpinteria, CA; Catalog # M823; dilution
1:150). Heat induced antigen retrieval was performed with
Ventana Benchmark Autostainer. The staining was optimized
using appropriate positive and negative controls.
Statistical analysis
T-tests and chi-square tests were used to compare continuous
and categorical clinical variables in patient demographics using
SAS 9.1.3 (SAS Institute Inc., Cary, NC). Protein concentration
data from ELISAs were compared between AR and STA using the
Mann-Whitney U test in R. P-values #0.05 were considered
statistically significant. The enrichment of known protein bio-
markers in differentially expressed genes was calculated using
Fisher’s exact test in R.
Supporting Information
Dataset S1 Predicted diagnostics protein biomarkers on 22
diseases.
Found at: doi:10.1371/journal.pcbi.1000940.s001 (1.39 MB XLS)
Figure S1 Histogram of overlapping genes in three transplant
rejection microarray datasets after shuffling gene labels. We shuffled
the gene labels in the three pediatric renal, adult renal and cardiac
transplant rejection gene expression data sets, calculated differen-
tially expressed AR genes in common. After repeating the processed
100,000 times, we plotted the distribution of the number of
overlapping genes (blue histogram). The probability of getting 17 or
more common genes by random is less than 1% and the probability
of getting 24 or more common genes is less than 1610-5(red curve).
Found at: doi:10.1371/journal.pcbi.1000940.s002 (0.95 MB
PDF)
Figure S2 Shared pathway for AR across solid-organ transplan-
tation. Among 45 genes that were upregulated in the AR
compared with stable biopsy samples across transplanted organs,
23 of them were involved in a single pro-inflammatory pathway
regulated by STAT-1. We tested 5 proteins (circled) from the
pathway by ELISA, and three of them (red circle) were validated
as cross-organ serum protein biomarkers for transplant rejection.
The 18 untested AR proteins from the 45 are highlighted in the
pathway, providing promising leads for further validation. Five of
them (red star) were known to have detectable levels of protein
expression in the normal serum or urine according to our human
biofluid proteome database. Seven of them (blue star) were studied
in knock-out mouse models, confirming their involvement in the
immune system.
Found at: doi:10.1371/journal.pcbi.1000940.s003 (0.59 MB PDF)
Figure S3 ROC curves predicting renal and cardiac AR using
PECAM1+CXCL9. ROC curves showed three-fold cross-valida-
tion results on predicting renal (solid curve) and cardiac (dotted
curve) transplant rejection (AR) from stable graft function using a
combined panel of PECAM1 and CXCL9 proteins in serum
(renal) and plasma (cardiac). The true positive rates were showed
as mean 6 standard error across 1,000 three-fold cross-validation.
It showed an improvement over individual proteins on cardiac AR
and no improvement on renal AR.
Found at: doi:10.1371/journal.pcbi.1000940.s004 (0.89 MB PDF)
Figure S4 Serum PECAM1 protein was significantly upregu-
lated in AR than BK virus infection, chronic allograft injury, and
stable graft function after renal transplant. The protein concen-
trations of PECAM1 was statistically significantly higher in the
serum samples of 18 patients with acute rejection (AR) than 10
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allograft injury (CAN) and 20 patients with stable graft function
(STA) serum samples after renal transplantation.
Found at: doi:10.1371/journal.pcbi.1000940.s005 (1.40 MB PDF)
Table S1 Patient demographics of AR versus STA allograft
biopsies in pediatric renal transplant microarray study.
Found at: doi:10.1371/journal.pcbi.1000940.s006 (0.05 MB
DOC)
Table S2 Forty-five AR genes commonly upregulated in biopsy-
based gene expression studies across solid-organ transplantation.
Found at: doi:10.1371/journal.pcbi.1000940.s007 (0.09 MB
DOC)
Table S3 Patient demographics of renal transplant in ELISA
study.
Found at: doi:10.1371/journal.pcbi.1000940.s008 (0.05 MB
DOC)
Table S4 Patient demographics of cardiac transplant in ELISA
study.
Found at: doi:10.1371/journal.pcbi.1000940.s009 (0.05 MB
DOC)
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